Aurigene Discovery Technologies Limited, a research, development, and manufacturing services organization and subsidiary of Dr. Reddy’s Laboratories, announced plans to construct a development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors in Genome Valley at Hyderabad, India. As the first phase of investment, Aurigene will invest $40 million in an R&D and pilot-scale facility. Scheduled for completion in the first half of 2024, the facility will meet process development and clinical supply needs for global biotech companies based on a flexible, multi-product design across therapeutic proteins, antibodies, and vectors.
This investment complements Aurigene’s expertise in biotherapeutics discovery and aims to accelerate global pharmaceutical companies’ progression of biologics from R&D to market by providing end-to-end, high-quality development and manufacturing services. Specific strengths highlighted include: a dedicated team with experience successfully commercializing several biosimilars globally; global regulatory experience; and seamless access to large-scale commercial manufacturing through Dr. Reddy’s facilities.
The expansion gives Aurigene customers exclusive access to modern R&D labs and a pilot manufacturing facility, complemented by access to an established large-scale GMP manufacturing facility with 15kl of drug substance capacity and fill-finish capabilities. An additional fill-finish line is also under construction to expand capacity before the end of 2024. With a strong track record of commercializing six biosimilars globally already, the Aurigene team is described as well-positioned to accelerate clients’ abilities to deliver novel biologics to patients.
Last updated: December 26th, 2025
